论文部分内容阅读
目的:检测组蛋白去乙酰化酶1(HDAC1)和组蛋白去乙酰化酶2(HDAC2)在前列腺癌中的表达情况,并探讨其临床意义。方法:选取82例临床资料完整的前列腺癌组织石蜡标本,免疫组化染色检测HDAC1和HDAC2蛋白的表达情况,分析其与Gleason分级、术前PSA水平、术后生存时间等指标的相关性。结果:免疫组化染色显示,前列腺癌组织中HDAC1和HDAC2的表达率分别为59.7%(49/82)、70.7%(58/82),定位于细胞核;Gleason评分高的患病组中HDAC1和HDAC2的表达高于Gleason评分低组,且在不同Gleason分级中表达差异有显著性(P均<0.05);HDAC1和HDAC2的表达在不同术前PSA水平、不同年龄分组中差异无统计学意义(P>0.05);单因素分析显示HDAC2、术前PSA水平、临床分期及Glesaon分级是影响前列腺癌患者生存的重要因素(P均<0.05);多因素回归分析表明HDAC2在前列腺癌中具有独立的预后意义(P=0.017,HR=2.265,95%CI:1.145～4.775)。结论:HDAC2在前列腺癌组织中表达升高并且具有独立的预后意义,为HDACs抑制剂在前列腺癌诊断中的应用和患者预后的判断提供了理论依据。
Objective: To detect the expression of histone deacetylase 1 (HDAC1) and histone deacetylase 2 (HDAC2) in prostate cancer and to explore its clinical significance. Methods: A total of 82 specimens of prostate cancer were collected. The expression of HDAC1 and HDAC2 protein were detected by immunohistochemical staining. The correlation between the expression of HDAC1 and HDAC2 protein and the Gleason grade, preoperative PSA level and postoperative survival time were analyzed. Results: Immunohistochemical staining showed that the expression rates of HDAC1 and HDAC2 in prostate cancer tissues were 59.7% (49/82) and 70.7% (58/82), respectively. The positive rates of HDAC1 and HDAC2 in the patients with high Gleason score The expression of HDAC2 was higher than that of the Gleason score group, and there was significant difference in the different Gleason grades (all P <0.05). The expression of HDAC1 and HDAC2 in different preoperative PSA levels had no significant difference P <0.05). Univariate analysis showed that HDAC2, preoperative PSA level, clinical stage and Glesaon grade were the important factors influencing the survival of patients with prostate cancer (all P <0.05). Multivariate regression analysis showed that HDAC2 had independent Prognostic significance (P = 0.017, HR = 2.265, 95% CI: 1.145-4.775). Conclusion: The expression of HDAC2 is increased in prostate cancer tissues and has an independent prognostic significance. It provides a theoretical basis for the application of HDACs inhibitors in the diagnosis of prostate cancer and the prognosis of patients.